You are here


Debra Auguste

327 ISEC
360 Huntington Avenue
Boston, MA 02115


Joined the Chemical Engineering Department in Fall 2016.


  • 2005 PhD in Chemical Engineering, Princeton University
  • 1999 SB in Chemical Engineering, MIT

Research & Scholarship Interests

Bioresponsive drug delivery; cell and tissue engineering; tissue architecture; targeted therapeutics
Affiliated With

Department Research Areas

Honors & Awards

  • 2012 Presidential Early Career Award in Science and Engineering (PECASE)
  • 2012 NIH Director’s New Innovator Award
  • 2011 NSF CAREER Award
  • 2010 Participant, National Academy of Engineering, Frontiers of Engineering Meeting
  • 2010 Named 50 Most Influential African-Americans in Technology
  • 2009 DARPA Young Faculty Award
  • 2007 Office of Naval Research Young Investigator Program Award

Professional Affiliations

  • American Chemical Society
  • American Institute of Chemical Engineers
  • Biomedical Engineering Society
  • Materials Research Society

Selected Publications

  • P. Guo, J. Yang, D. Jia, M.A. Moses, D.T. Auguste, ICAM-1-Targeted, Lcn2 siRNA-Encapsulated Liposomes are Potent Anti-Angiogenic Agents for Triple Negative Breast Cancer, Theranostics, 6, 2016, 1-13
  • D. Liu, D.T. Auguste, Cancer Targeted Therapeutics: From Molecules to Drug Delivery Vehicles, Journal of Controlled Release, 219, 2015, 632-643
  • B. Wang, P. Guo, D.T. Auguste, Mapping the CXCR4 Receptor on Breast Cancer Cells, Biomaterials, 57, 2015, 161-8
  • T.T. Ho, J.O. You, D.T. Auguste, siRNA Delivery Impedes the Temporal Expression of Cytokine-Activated VCAM1 on Endothelial Cells, Annals of Biomedical Engineering, 2015, 1-8
  • J.O. You, M. Rafat, D. Almeda, N. Maldonado, P. Guo, C.S. Nabzdyk, M. Chun, F.W. LoGerfo, J.W. Hutchinson, L.K. Pradhan-Nabsdyk, D.T. Auguste, pH-Responsive Scaffolds Generate a Pro-Healing Response, Biomaterials, 57, 2015, 22-32
  • D. Almeda, B. Wang, D.T. Auguste, Minimizing Antibody Surface Density on Lipsomes While Sustaining Cytokine-Activated EC Targeting, Biomaterials, 47, 2015, 37-44
  • P. Guo, J. Huang, L. Wang, D. Jia, J. Yang, D.A. Dillon, D. Zurakowski, H. Mao, M.A. Moses, D.T. Auguste, ICAM-1 as a Molecular Target for Triple Negative Breast Cancer, Proceedings of the National Academy of Science, 111(41), 2014, 14710-14715
  • P. Guo, J.O. You, J. Yang, D. Jia, M.A. Moses, D.T. Auguste, Inhibiting Metstatic Breast Cancer Cell Migration Via the Synergy of Targeted, pH-Triggered siRNA Delivery and Chemokine Axis Blockade, Molecular Pharmaceutics, 11(3), 2014, 755-765
  • J. You, P. Guo, D.T. Auguste, A Multi-Targeted Drug Delivery Vehicle Approach that Targets, Triggers, and Thermally Ablates HER2+ Breast Cancer Cells, Angewandte Chemie, 52(15), 2013, 4141-4146

Related News

April 3, 2019

ChE Professor Debra Auguste is collaborating with Boston Children's Hospital to develop new treatments to target and treat patients with triple-negative breast cancer.

April 1, 2019

ChE Professor Debra Auguste's article on "Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1/FOXM1+ Triple Negative Breast Cancer Cells" published in Molecular Pharmaceutics.

March 21, 2019

Chemical Engineering Professor Debra Auguste’s research paper, Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis, was recently published in Sciences Advances journal.